The funding will allow the company to develop the ShigETEC, an orally administered vaccine candidate that offers broad protection against Shigella and ETEC, through phase II clinical testing. ShigETEC is derived from a live attenuated Shigella vaccine strain rationally designed to address the shortcomings of previous vaccine attempts and protects against both pathogens.

Shigella and ETEC are two major pathogens of diarrheal diseases among children under the age of five living in low- and middle-income countries.

The institute awarded a base award of $215,093 with a total contract value of $20.6 million if all contract options are exercised. The options cover milestones, like covering the investigational new drug filing at the U.S. Food and Drug Administration, manufacturing clinical trial material, and several human challenge studies to prove the vaccine's effectiveness.

Intravacc receives NIH award to develop enterovirus D68 vaccine
Intravacc has been awarded a $9.4 million contract from the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes...

Microbe-based platform aims for sweet spot between biologics and gene therapy
A microbe-based therapeutics platform that has been in development for nearly 30 years is gaining traction for the treatment of inflammatory and autoimmune...

NIH leads adaptive phase II clinical trial for COVID-19 mAb
The National Institutes of Health (NIH) is now studying an investigational monoclonal antibody (mAb), Ly-CoV555, as part of an adaptive phase II clinical...